StrokeNCT06955182
Dynamic Hot Spring Hydrotherapy for Gait Disorders and Balance Function Recovery After Stroke
A study testing Dynamic hot spring hydrotherapy intervention and Conventional rehabilitation intervention in people with Stroke, run by The Second Affiliated Hospital of Kunming Medical University at 1 site in China.
Trial summary
Our research aims to analyze and compare the improvement of various indicators of gait disorders and balance function before and after dynamic hot spring hydrotherapy and conventional exercise intervention, and clarify the therapeutic effect of dynamic hot spring hydrotherapy on gait disorders and balance function in… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Stroke
- What is being tested?
- Dynamic hot spring hydrotherapy intervention and Conventional rehabilitation intervention
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteChina
- Study dates
- May 2025to 30 Mar 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with cerebral infarction or cerebral hemorrhage who meet the diagnostic criteria for stroke of the Chinese Medical Association; (2) Initial stroke<6 months, or last stroke event>6 months; (3) Age>=18 years old,<85 years old (increased risk of VCI over 85 years old); (4) NIHSS>4, NIHSS<26 points; (5) MRS score>=2 points; (6) complete CT or MRI; (7) No serious neurological or mental illness; Unconscious disorders, able to cooperate with relevant treatments; No severe cognitive impairment (MMSE>=15 points); (8) Berg Balance Scale>40 points; (9) The patient or family member signs an informed consent form.
Who cannot join
- (1) Concurrent major diseases, such as heart, lung, liver, kidney and other organ diseases or failure; (2) There are contraindications for hydrotherapy such as acute infectious diseases, open skin wounds, and severe epilepsy; (3) There are other clinical issues that may affect the assessment results, such as low vision, fractures, vestibular diseases, etc; (4) There are other neurological disorders, such as multiple sclerosis, Parkinson's disease, etc; (5) Serious mental and psychological problems exist; (6) Malignant tumor patients; (7) Early pregnancy or high-risk pregnancy; (8) Serious alcohol abusers; (9) Patients with active bleeding, such as gastrointestinal bleeding, nosebleeds, and excessive menstruation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Electroencephalography
Kunming, Yunnan
Yao, +8613529202383, yaoliqing98731@163.com
About this study
Our research aims to analyze and compare the improvement of various indicators of gait disorders and balance function before and after dynamic hot spring hydrotherapy and conventional exercise intervention, and clarify the therapeutic effect of dynamic hot spring hydrotherapy on gait disorders and balance function in stroke patients.
- Conditions
- Stroke
- Being tested
- Dynamic hot spring hydrotherapy intervention, Conventional rehabilitation intervention
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dynamic hot spring hydrotherapy interventionOther
Under closed management, patients will receive 5 times a week, 20 minutes of routine rehabilitation and 20 minutes of hot spring water exercise each time: (1) 20 minutes of routine rehabilitation: including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); (2) 20 minute hot spring water balance walking function training
Conventional rehabilitation interventionOther
Under closed management, patients will receive routine physical therapy for 40 minutes 5 times a week: 1) 20 minutes of routine rehabilitation, including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); 2) 20 minute land balance walking function training
| Study group | Role | What they receive |
|---|---|---|
| Conventional rehabilitation intervention | Sham comparator | Under closed management, patients will receive routine physical therapy for 40 minutes 5 times a week: 1) 20 minutes of routine rehabilitation, including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); 2) 20 minute land balance walking function training Receives: Other: Conventional rehabilitation intervention |
| Dynamic hot spring hydrotherapy intervention | Experimental | Under closed management, patients will receive 5 times a week, 20 minutes of routine rehabilitation and 20 minutes of hot spring water exercise each time: (1) 20 minutes of routine rehabilitation: including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); (2) 20 minute hot spring water balance walking function training Receives: Other: Dynamic hot spring hydrotherapy intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Timed Up and Go Test, (TUG)
Timed Stand Up Walking Test (TUG)
Assess gait based on the time required for the test subject to stand up from the chair, walk at a steady pace to the 3-meter mark, and then return to the chair to sit down. The evaluation results are as follows:
<10 seconds: Normal activity ability, low risk of falling. 10-14 seconds: There may be mild functional impairment, further evaluation is needed.
>14 seconds: The risk of falling significantly increases (such as in elderly people or Parkinson's disease patients).
>20 seconds: Prompt for severe mobility impairment, requiring intervention (such as in post-stroke patients).
Measured: From enrollment to the end of treatment at 2 weeks.
10 Meter Walk Test, (10WMT)
Individuals walk 10 meters and have participants conduct 3 trials at a comfortable walking speed, followed by 3 trials at the patient's fast walking speed. Measure the middle 6 meters, allowing for acceleration and deceleration. The timing starts when the toe of the current foot crosses the 2-meter mark; The timer ends when the toe of the current foot crosses the 8-meter mark; In units of s, accurate to two decimal places; Calculate the average for each walking speed. The actual speed is 6m divided by the recorded seconds to obtain the speed in m/s. The speed rating results are as follows:
<0.4m/s can be used for family walking 0.4-0.8m/s allows for limited community walking >0.8m/s can be used for community walking If the test subject requires full assistance, a score of 0 should be recorded.
Measured: From enrollment to the end of treatment at 2 weeks.
Berg Balance Scale, BBS
The BBS consists of 14 projects, including sitting to stand, standing independently, sitting independently, standing to sit, bed chair transfer, standing with closed eyes, standing with both feet together, extending the upper limbs in the standing position, picking up objects from the ground in the standing position, turning around to look back, turning around once, alternating steps with both feet, standing on one leg, etc. Each project is rated from 0 to 4 points based on the patient's completion status, with a total score of 56 points. The evaluation results are as follows:
41-56 points: Good balance function, low risk of falling 21-40 points: There is a certain degree of decline in balance function, and the risk of falling is moderate 0-20 points: Severe impairment of balance function, high risk of falling
Measured: From enrollment to the end of treatment at 2 weeks.
Fugl-Meyer Balance Assessment,（FMA-B)
The ability of the test subject to complete various balance test items, including unsupported sitting; Healthy side "spreading wings" reaction; The completion of the "spreading wings" reaction on the affected side, standing with support, standing without support, standing on the healthy side, and standing on the affected side will be scored. Each examination item will be scored on a scale of 0-2 points, with the highest score of 14 points and the lowest score of 0 points. If the score is less than 14 points, it indicates that the balance function is impaired. The lower the score, the more severe the balance dysfunction.
Measured: From enrollment to the end of treatment at 2 weeks.
Forced Vital Capacity, (FVC).
Typically, adult males consume 3000~5000ml, while females consume 2000~4000 liters.
Measured: From enrollment to the end of treatment at 2 weeks.
FEV1
The amount of gas exhaled in the first second is approximately 3179 ± 117mL for normal males and 2314 ± 48mL for females, starting from the maximum inhalation to the level of total lung volume.
Measured: From enrollment to the end of treatment at 2 weeks.
Maximum Voluntary Ventilation, (MVV)
The general normal standard for pulmonary function MVV is: Male: （104+2.71)L/min； female sex: （82.5+2.17）L/min。
Measured: From enrollment to the end of treatment at 2 weeks.
VO2
The maximum amount of oxygen that the human body can absorb per unit time during exercise is usually measured in milliliters per minute (ml/min). VO2 reflects the cardiovascular function and aerobic exercise capacity of the human body, and is an important indicator for evaluating human endurance.
Measured: From enrollment to the end of treatment at 2 weeks.
oxygen consumption per kg body weight, (VO2/Kg)
Oxygen consumption per unit weight (kg) per unit time. Expressed in VO2/kg. It is an indicator of an individual's athletic ability.The unit is mL/(kg · min).
Measured: From enrollment to the end of treatment at 2 weeks.
METS
METs (metabolic equivalents) are indicators of energy expenditure during physical activity. 1 MET is equal to the oxygen consumption during sitting (approximately 3.5 mL/kg/min).
Measured: From enrollment to the end of treatment at 2 weeks.
Respiratory Quotient, (RQ)
RQ refers to the ratio of carbon dioxide production to oxygen consumption in the body, and is commonly used to evaluate the energy metabolism of the body in different states. The numerical range of RQ is between 0.67 and 1.3.
Measured: From enrollment to the end of treatment at 2 weeks.
VE
It is the amount of ventilation that maintains normal gas exchange in a resting state, equal to tidal volume multiplied by respiratory rate per minute.The unit is L/min.
Measured: From enrollment to the end of treatment at 2 weeks.
breathing reserve ratio
BR=Maximum Ventilation Volume (MVV) - Minute Ventilation Volume during Maximum Exercise (VE).Normal respiratory reserve should be greater than 15L/min, indicating normal dynamic lung function levels in the body.
Measured: From enrollment to the end of treatment at 2 weeks.
Tidal Volume, (VT)
VT is the amount of gas entering and leaving the lungs during each breath, reflecting the ventilation function of the lungs. The normal range for adults is about 6-8 milliliters per kilogram of body weight.
Measured: From enrollment to the end of treatment at 2 weeks.
Heart Rate, (HR)
Heart rate is an important indicator of the human cardiovascular system, which reflects the functional status of the heart. HR can refer to instantaneous heart rate, measured in beats per minute.
Measured: From enrollment to the end of treatment at 2 weeks.
VO2/WR
Under normal physiological conditions, there is a linear relationship between VO2 and the power of the human body to do work, commonly expressed as VO2/WR, with the unit of m/(min · W). The normal value is 8.4~11ml/(min · W). Decreased VO2/WR often indicates impaired oxygen delivery.
Measured: From enrollment to the end of treatment at 2 weeks.
The oxygen pulse (VO2/HR)
The oxygen pulse is calculated by dividing VO2 by the heart rate at the same time. It is the amount of oxygen taken into the lung blood during one heart beat, which is equal to the product of the output per beat and the arterial mixed venous oxygen content difference [C (a-v) O2]. Its unit is ml/kg/min.
Measured: From enrollment to the end of treatment at 2 weeks.
VO2@AT
It refers to the oxygen uptake at the anaerobic threshold (AT). The normal value of peakVO2 is usually greater than 40%, which is equivalent to 50%~65% peakVO2.
Measured: From enrollment to the end of treatment at 2 weeks.
PetCO2
It refers to the pressure value of carbon dioxide in the exhaled gas at the end of exhalation. By monitoring PetCO2, the condition of lung ventilation and blood flow can be reflected. The normal value of PetCO2 (end tidal carbon dioxide partial pressure) is 35-45 mmHg.
Measured: From enrollment to the end of treatment at 2 weeks.
PetO2
It reflects the oxygen partial pressure in the alveolar gas at the end of exhalation, and the normal range of PetO2 is 95-100mmHg
Measured: From enrollment to the end of treatment at 2 weeks.
VE/VO2
VE/VO2 refers to the ratio of minute ventilation to minute oxygen consumption, which is normally between 25-35.
Measured: From enrollment to the end of treatment at 2 weeks.
VE/VCO2
VE/VCO2 refers to the ratio of minute ventilation to minute carbon dioxide emissions, with a normal range of 30-40.
Measured: From enrollment to the end of treatment at 2 weeks.
SpO2
SpO2 refers to pulse oximetry, and the normal range of SpO ₂ for normal adults in a calm breathing state at sea level is 95% -100%.
Measured: From enrollment to the end of treatment at 2 weeks.
HR_1_minute
It usually refers to the number of heartbeats counted within one minute, with a focus on specific heart rate values per minute. Under normal circumstances, the heart rate of adults in a quiet state is generally 60-100 beats per minute.
Measured: From enrollment to the end of treatment at 2 weeks.
P Syst
It refers to the pressure exerted by blood on the walls of blood vessels during cardiac contraction, at which the ventricles pump blood into the aorta, causing the pressure inside the aorta to rise to its highest value, usually measured in mmHg (millimeter of mercury). The normal range of systolic blood pressure for normal adults in a quiet state is usually 90-139mmHg.
Measured: From enrollment to the end of treatment at 2 weeks.
P Diast
It is the pressure exerted on the blood vessel walls during diastole, when the ventricles are in a filled state and the pressure inside the aorta drops to its lowest value. The normal range of diastolic blood pressure for normal adults in a quiet state is generally 60-89mmHg.
Measured: From enrollment to the end of treatment at 2 weeks.
Step Length
The horizontal distance from the same foot following the ground to the opposite foot following the ground (left/right step lengths may be asymmetric).Its unit is meters.
Measured: From enrollment to the end of treatment at 2 weeks.
Stride Length
The horizontal distance between two consecutive landings of the heel on the same side (one complete gait cycle).Its unit is meters.
Measured: From enrollment to the end of treatment at 2 weeks.
Step Width
The lateral distance between the inner edges of both feet, reflecting walking stability.Its unit is meters.
Measured: From enrollment to the end of treatment at 2 weeks.
Cadence
Steps per minute (steps/minute), typically around 100-120 steps for adults.
Measured: From enrollment to the end of treatment at 2 weeks.
Walking Speed
The distance traveled per unit of time (in meters per second), which comprehensively reflects gait function.
Measured: From enrollment to the end of treatment at 2 weeks.
Stance Phase
The proportion of time the foot is in contact with the ground (approximately 60% of the normal gait cycle).
Measured: From enrollment to the end of treatment at 2 weeks.
Swing Phase
The proportion of time spent swinging the foot off the ground (usually around 40%).
Measured: From enrollment to the end of treatment at 2 weeks.
Double Support
The time for both feet to touch the ground simultaneously (prolonged when the pace slows down).Its unit is seconds.
Measured: From enrollment to the end of treatment at 2 weeks.
Hip joint
Sagittal flexion/extension (normal range of approximately 30 ° flexion to 10 ° extension).
Measured: From enrollment to the end of treatment at 2 weeks.
Knee joint
Sagittal plane flexion (0 ° extension to 60 ° flexion swing phase).
Measured: From enrollment to the end of treatment at 2 weeks.
Ankle joint
Sagittal dorsiflexion/plantarflexion (dorsiflexion when the foot touches the ground, plantarflexion during advancement).
Measured: From enrollment to the end of treatment at 2 weeks.
Pelvic movements
Forward/backward tilt, internal and external rotation, lateral tilt.
Measured: From enrollment to the end of treatment at 2 weeks.
Ground Reaction Force (GRF)
Measured by a force measuring platform, a typical bimodal curve (first peak ≈ 110% of body weight, second peak ≈ 120% of body weight).
Measured: From enrollment to the end of treatment at 2 weeks.
Joint Moments
Reflecting the control of muscles and ligaments over joints (such as predicting the risk of osteoarthritis with knee adduction torque).The unit of it is N · m (Newton meters)
Measured: From enrollment to the end of treatment at 2 weeks.
Power
Joint work efficiency (peak power during ankle joint propulsion is key).The unit it is W.
Measured: From enrollment to the end of treatment at 2 weeks.
Symmetry Index
The difference in step size and support phase time between the left and right sides (often asymmetric in stroke patients).
Measured: From enrollment to the end of treatment at 2 weeks.
Phase Coordination
The temporal relationship between the swing phase and the support phase (which may be disrupted in Parkinson's disease patients).
Measured: From enrollment to the end of treatment at 2 weeks.
Center of gravity position
It refers to the projection position of the center of gravity on the horizontal plane when the human body is standing quietly. By using pressure tablets and other devices, the front, back, left, and right positions of the center of gravity can be measured, reflecting the body's balance state under static conditions. Under normal circumstances, the center of gravity is relatively stable and within the range of the area supported by both feet.
Measured: From enrollment to the end of treatment at 2 weeks.
Center of gravity swing amplitude
It refers to the maximum distance that the center of gravity deviates from the center position within a certain period of time. The smaller the swing amplitude, the better the static balance ability. Generally measured in millimeters (mm), when healthy adults stand quietly, the amplitude of their center of gravity swing back and forth is usually around 10-20mm, and the amplitude of left and right swing is relatively small.
Measured: From enrollment to the end of treatment at 2 weeks.
Center of gravity swing frequency
It refers to the number of times the center of gravity swings per unit time. The lower the frequency, the stronger the static balance control capability. When a normal adult stands quietly, the frequency of center of gravity swing is generally between 0.5-2 times per second.
Measured: From enrollment to the end of treatment at 2 weeks.
Walking stability
It is evaluated by analyzing the step characteristics during walking, including step length, stride length, step frequency, bipedal support time, single foot support time, and other parameters. For example, if the stride is uniform, the stride is stable, the stride frequency is moderate, and the ratio of foot support time to single foot support time is reasonable, it indicates good dynamic balance ability during walking. When adults walk normally, the stride length is about 50-80cm, and the step frequency is around 90-120 steps per minute.
Measured: From enrollment to the end of treatment at 2 weeks.
Posture transition ability
It measures the stability and coordination during the transition from one posture to another (such as sitting to standing, standing to walking, etc.). The evaluation indicators include conversion time, accuracy of center of gravity shift, and whether additional support or auxiliary movements are needed. Healthy individuals complete posture transitions quickly and smoothly, with a smooth shift of center of gravity, typically without the need for external force or excessive adjustment movements.
Measured: From enrollment to the end of treatment at 2 weeks.
Disturbance response ability
The ability of the human body to restore balance through its own balance adjustment mechanism when subjected to external disturbances such as sudden thrust, tension, or ground shaking. The relevant parameters include reaction time, maximum offset distance, and time to restore balance. Rapid response, ability to control the body's center of gravity within a small deviation range and quickly restore balance, indicate good disturbance response ability.
Measured: From enrollment to the end of treatment at 2 weeks.
Visual dependence level
It is evaluated by comparing the balance test results between open and closed eye states. If the balance function significantly decreases after closing the eyes, it indicates a high degree of dependence on visual information; On the contrary, if there is not much difference in balance performance between opening and closing the eyes, it indicates that other balance regulation mechanisms such as proprioception have played a good role. For example, in the test of standing on one foot with closed eyes, the ability to stand for a longer period of time when the eyes are open is significantly reduced, indicating that vision plays an important role in maintaining balance in this posture.
Measured: From enrollment to the end of treatment at 2 weeks.
Muscle activity pattern
Using techniques such as surface electromyography to record the activation sequence, intensity, and duration of different muscles during balance tasks. Normal balance control requires multiple groups of muscles to work together, and whether the muscle activity pattern is normal or not can reflect the nervous system's ability to control muscles and the coordination and cooperation between muscles. For example, when maintaining balance in a standing position, the calf muscles, hip muscles, and back muscles will contract and relax in a timely manner according to changes in the body's center of gravity to maintain stability.
Measured: From enrollment to the end of treatment at 2 weeks.
Secondary outcomes (4)
anxiety
Beck Anxiety Inventory Scoring is based on the severity of anxiety symptoms, and the total score is calculated by adding up each result. Scores 15-25 indicate mild anxiety, 26-35 indicate moderate anxiety, and scores above 36 indicate severe anxiety.
Measured: From enrollment to the end of treatment at 2 weeks
sleep quality
Pittsburgh Sleep Quality Index (PSQI) According to the various indicators of sleep quality, the frequency is divided into 0-5 points: good sleep quality, 6-10 points: decent sleep quality, 11-15 points: average sleep quality, 16-21 points: poor sleep quality.
Measured: From enrollment to the end of treatment at 2 weeks
Self efficacy
ABC Balanced Confidence Scale Based on the confidence level of each item, ranging from 0% (no confidence) to 100% (completely confident), the total score is taken as the average of all items.
≥ 80%: Good balance and confidence, low risk of falling; 50%~80%: moderate risk; <50%: High risk, requiring intervention.
Measured: From enrollment to the end of treatment at 2 weeks
Neurotransmitters and Cytokines
β - endorphin, tumor necrosis factor - α (TNF - α), and interleukin-6 (IL-6)
Measured: From enrollment to the end of treatment at 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2025
- Study startMay 2025 (estimated)
- Primary completion20 Jan 2026 (estimated)
- Study completion30 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Second Affiliated Hospital of Kunming Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Liqing Yao, The Second Affiliated Hospital of Kunming Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06955182
- Sponsor's protocol ID
- Shen-PJ-Ke-2025-19
- Status last verified
- Apr 2025
- First submitted
- 14 Apr 2025
- Last updated
- 2 May 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dynamic Hot Spring Hydrotherapy for Gait Disorders and Balance Function Recovery After Stroke
- ClinicalTrials.gov ID
- NCT06955182
- Acronym / sponsor ID
- Shen-PJ-Ke-2025-19
- Conditions
- Stroke
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- The Second Affiliated Hospital of Kunming Medical UniversityUniversity, hospital or other
- Study start
- May 2025 (estimated)
- Primary completion
- 20 Jan 2026 (estimated)
- Study completion
- 30 Mar 2026 (estimated)
- First posted
- 2 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our research aims to analyze and compare the improvement of various indicators of gait disorders and balance function before and after dynamic hot spring hydrotherapy and conventional exercise intervention, and clarify the therapeutic effect of dynamic hot spring hydrotherapy on gait disorders and balance function in stroke patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Conventional rehabilitation intervention | Sham comparator | Other: Conventional rehabilitation interventionUnder closed management, patients will receive routine physical therapy for 40 minutes 5 times a week: 1) 20 minutes of routine rehabilitation, including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); 2) 20 minute land balance walking function training |
| Dynamic hot spring hydrotherapy intervention | Experimental | Other: Dynamic hot spring hydrotherapy interventionUnder closed management, patients will receive 5 times a week, 20 minutes of routine rehabilitation and 20 minutes of hot spring water exercise each time: (1) 20 minutes of routine rehabilitation: including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); (2) 20 minute hot spring water balance walking function training |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with cerebral infarction or cerebral hemorrhage who meet the diagnostic criteria for stroke of the Chinese Medical Association; (2) Initial stroke<6 months, or last stroke event>6 months; (3) Age>=18 years old,<85 years old (increased risk of VCI over 85 years old); (4) NIHSS>4, NIHSS<26 points; (5) MRS score>=2 points; (6) complete CT or MRI; (7) No serious neurological or mental illness; Unconscious disorders, able to cooperate with relevant treatments; No severe cognitive impairment (MMSE>=15 points); (8) Berg Balance Scale>40 points; (9) The patient or family member signs an informed consent form.
Key exclusion criteria (1 listed)
- (1) Concurrent major diseases, such as heart, lung, liver, kidney and other organ diseases or failure; (2) There are contraindications for hydrotherapy such as acute infectious diseases, open skin wounds, and severe epilepsy; (3) There are other clinical issues that may affect the assessment results, such as low vision, fractures, vestibular diseases, etc; (4) There are other neurological disorders, such as multiple sclerosis, Parkinson's disease, etc; (5) Serious mental and psychological problems exist; (6) Malignant tumor patients; (7) Early pregnancy or high-risk pregnancy; (8) Serious alcohol abusers; (9) Patients with active bleeding, such as gastrointestinal bleeding, nosebleeds, and excessive menstruation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dynamic hot spring hydrotherapy interventionUnder closed management, patients will receive 5 times a week, 20 minutes of routine rehabilitation and 20 minutes of hot spring water exercise each time: (1) 20 minutes of routine rehabilitation: including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); (2) 20 minute hot spring water balance walking function training | Other | Dynamic hot spring hydrotherapy intervention |
| Conventional rehabilitation interventionUnder closed management, patients will receive routine physical therapy for 40 minutes 5 times a week: 1) 20 minutes of routine rehabilitation, including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); 2) 20 minute land balance walking function training | Other | Conventional rehabilitation intervention |
Primary outcome
Timed Up and Go Test, (TUG)
Time frame: From enrollment to the end of treatment at 2 weeks.
Timed Stand Up Walking Test (TUG) Assess gait based on the time required for the test subject to stand up from the chair, walk at a steady pace to the 3-meter mark, and then return to the chair to sit down. The evaluation results are as follows: <10 seconds: Normal activity ability, low risk of falling. 10-14 seconds: There may be mild functional impairment, further evaluation is needed. >14 seconds: The risk of falling significantly increases (such as in elderly people or Parkinson's disease patients). >20 seconds: Prompt for severe mobility impairment, requiring intervention (such as in post-stroke patients).
10 Meter Walk Test, (10WMT)
Time frame: From enrollment to the end of treatment at 2 weeks.
Individuals walk 10 meters and have participants conduct 3 trials at a comfortable walking speed, followed by 3 trials at the patient's fast walking speed. Measure the middle 6 meters, allowing for acceleration and deceleration. The timing starts when the toe of the current foot crosses the 2-meter mark; The timer ends when the toe of the current foot crosses the 8-meter mark; In units of s, accurate to two decimal places; Calculate the average for each walking speed. The actual speed is 6m divided by the recorded seconds to obtain the speed in m/s. The speed rating results are as follows: <0.4m/s can be used for family walking 0.4-0.8m/s allows for limited community walking >0.8m/s can be used for community walking If the test subject requires full assistance, a score of 0 should be recorded.
Berg Balance Scale, BBS
Time frame: From enrollment to the end of treatment at 2 weeks.
The BBS consists of 14 projects, including sitting to stand, standing independently, sitting independently, standing to sit, bed chair transfer, standing with closed eyes, standing with both feet together, extending the upper limbs in the standing position, picking up objects from the ground in the standing position, turning around to look back, turning around once, alternating steps with both feet, standing on one leg, etc. Each project is rated from 0 to 4 points based on the patient's completion status, with a total score of 56 points. The evaluation results are as follows: 41-56 points: Good balance function, low risk of falling 21-40 points: There is a certain degree of decline in balance function, and the risk of falling is moderate 0-20 points: Severe impairment of balance function, high risk of falling
Fugl-Meyer Balance Assessment,（FMA-B)
Time frame: From enrollment to the end of treatment at 2 weeks.
The ability of the test subject to complete various balance test items, including unsupported sitting; Healthy side "spreading wings" reaction; The completion of the "spreading wings" reaction on the affected side, standing with support, standing without support, standing on the healthy side, and standing on the affected side will be scored. Each examination item will be scored on a scale of 0-2 points, with the highest score of 14 points and the lowest score of 0 points. If the score is less than 14 points, it indicates that the balance function is impaired. The lower the score, the more severe the balance dysfunction.
Forced Vital Capacity, (FVC).
Time frame: From enrollment to the end of treatment at 2 weeks.
Typically, adult males consume 3000~5000ml, while females consume 2000~4000 liters.
FEV1
Time frame: From enrollment to the end of treatment at 2 weeks.
The amount of gas exhaled in the first second is approximately 3179 ± 117mL for normal males and 2314 ± 48mL for females, starting from the maximum inhalation to the level of total lung volume.
Maximum Voluntary Ventilation, (MVV)
Time frame: From enrollment to the end of treatment at 2 weeks.
The general normal standard for pulmonary function MVV is: Male: （104+2.71)L/min； female sex: （82.5+2.17）L/min。
VO2
Time frame: From enrollment to the end of treatment at 2 weeks.
The maximum amount of oxygen that the human body can absorb per unit time during exercise is usually measured in milliliters per minute (ml/min). VO2 reflects the cardiovascular function and aerobic exercise capacity of the human body, and is an important indicator for evaluating human endurance.
oxygen consumption per kg body weight, (VO2/Kg)
Time frame: From enrollment to the end of treatment at 2 weeks.
Oxygen consumption per unit weight (kg) per unit time. Expressed in VO2/kg. It is an indicator of an individual's athletic ability.The unit is mL/(kg · min).
METS
Time frame: From enrollment to the end of treatment at 2 weeks.
METs (metabolic equivalents) are indicators of energy expenditure during physical activity. 1 MET is equal to the oxygen consumption during sitting (approximately 3.5 mL/kg/min).
Respiratory Quotient, (RQ)
Time frame: From enrollment to the end of treatment at 2 weeks.
RQ refers to the ratio of carbon dioxide production to oxygen consumption in the body, and is commonly used to evaluate the energy metabolism of the body in different states. The numerical range of RQ is between 0.67 and 1.3.
VE
Time frame: From enrollment to the end of treatment at 2 weeks.
It is the amount of ventilation that maintains normal gas exchange in a resting state, equal to tidal volume multiplied by respiratory rate per minute.The unit is L/min.
breathing reserve ratio
Time frame: From enrollment to the end of treatment at 2 weeks.
BR=Maximum Ventilation Volume (MVV) - Minute Ventilation Volume during Maximum Exercise (VE).Normal respiratory reserve should be greater than 15L/min, indicating normal dynamic lung function levels in the body.
Tidal Volume, (VT)
Time frame: From enrollment to the end of treatment at 2 weeks.
VT is the amount of gas entering and leaving the lungs during each breath, reflecting the ventilation function of the lungs. The normal range for adults is about 6-8 milliliters per kilogram of body weight.
Heart Rate, (HR)
Time frame: From enrollment to the end of treatment at 2 weeks.
Heart rate is an important indicator of the human cardiovascular system, which reflects the functional status of the heart. HR can refer to instantaneous heart rate, measured in beats per minute.
VO2/WR
Time frame: From enrollment to the end of treatment at 2 weeks.
Under normal physiological conditions, there is a linear relationship between VO2 and the power of the human body to do work, commonly expressed as VO2/WR, with the unit of m/(min · W). The normal value is 8.4~11ml/(min · W). Decreased VO2/WR often indicates impaired oxygen delivery.
The oxygen pulse (VO2/HR)
Time frame: From enrollment to the end of treatment at 2 weeks.
The oxygen pulse is calculated by dividing VO2 by the heart rate at the same time. It is the amount of oxygen taken into the lung blood during one heart beat, which is equal to the product of the output per beat and the arterial mixed venous oxygen content difference [C (a-v) O2]. Its unit is ml/kg/min.
VO2@AT
Time frame: From enrollment to the end of treatment at 2 weeks.
It refers to the oxygen uptake at the anaerobic threshold (AT). The normal value of peakVO2 is usually greater than 40%, which is equivalent to 50%~65% peakVO2.
PetCO2
Time frame: From enrollment to the end of treatment at 2 weeks.
It refers to the pressure value of carbon dioxide in the exhaled gas at the end of exhalation. By monitoring PetCO2, the condition of lung ventilation and blood flow can be reflected. The normal value of PetCO2 (end tidal carbon dioxide partial pressure) is 35-45 mmHg.
PetO2
Time frame: From enrollment to the end of treatment at 2 weeks.
It reflects the oxygen partial pressure in the alveolar gas at the end of exhalation, and the normal range of PetO2 is 95-100mmHg
VE/VO2
Time frame: From enrollment to the end of treatment at 2 weeks.
VE/VO2 refers to the ratio of minute ventilation to minute oxygen consumption, which is normally between 25-35.
VE/VCO2
Time frame: From enrollment to the end of treatment at 2 weeks.
VE/VCO2 refers to the ratio of minute ventilation to minute carbon dioxide emissions, with a normal range of 30-40.
SpO2
Time frame: From enrollment to the end of treatment at 2 weeks.
SpO2 refers to pulse oximetry, and the normal range of SpO ₂ for normal adults in a calm breathing state at sea level is 95% -100%.
HR_1_minute
Time frame: From enrollment to the end of treatment at 2 weeks.
It usually refers to the number of heartbeats counted within one minute, with a focus on specific heart rate values per minute. Under normal circumstances, the heart rate of adults in a quiet state is generally 60-100 beats per minute.
P Syst
Time frame: From enrollment to the end of treatment at 2 weeks.
It refers to the pressure exerted by blood on the walls of blood vessels during cardiac contraction, at which the ventricles pump blood into the aorta, causing the pressure inside the aorta to rise to its highest value, usually measured in mmHg (millimeter of mercury). The normal range of systolic blood pressure for normal adults in a quiet state is usually 90-139mmHg.
P Diast
Time frame: From enrollment to the end of treatment at 2 weeks.
It is the pressure exerted on the blood vessel walls during diastole, when the ventricles are in a filled state and the pressure inside the aorta drops to its lowest value. The normal range of diastolic blood pressure for normal adults in a quiet state is generally 60-89mmHg.
Step Length
Time frame: From enrollment to the end of treatment at 2 weeks.
The horizontal distance from the same foot following the ground to the opposite foot following the ground (left/right step lengths may be asymmetric).Its unit is meters.
Stride Length
Time frame: From enrollment to the end of treatment at 2 weeks.
The horizontal distance between two consecutive landings of the heel on the same side (one complete gait cycle).Its unit is meters.
Step Width
Time frame: From enrollment to the end of treatment at 2 weeks.
The lateral distance between the inner edges of both feet, reflecting walking stability.Its unit is meters.
Cadence
Time frame: From enrollment to the end of treatment at 2 weeks.
Steps per minute (steps/minute), typically around 100-120 steps for adults.
Walking Speed
Time frame: From enrollment to the end of treatment at 2 weeks.
The distance traveled per unit of time (in meters per second), which comprehensively reflects gait function.
Stance Phase
Time frame: From enrollment to the end of treatment at 2 weeks.
The proportion of time the foot is in contact with the ground (approximately 60% of the normal gait cycle).
Swing Phase
Time frame: From enrollment to the end of treatment at 2 weeks.
The proportion of time spent swinging the foot off the ground (usually around 40%).
Double Support
Time frame: From enrollment to the end of treatment at 2 weeks.
The time for both feet to touch the ground simultaneously (prolonged when the pace slows down).Its unit is seconds.
Hip joint
Time frame: From enrollment to the end of treatment at 2 weeks.
Sagittal flexion/extension (normal range of approximately 30 ° flexion to 10 ° extension).
Knee joint
Time frame: From enrollment to the end of treatment at 2 weeks.
Sagittal plane flexion (0 ° extension to 60 ° flexion swing phase).
Ankle joint
Time frame: From enrollment to the end of treatment at 2 weeks.
Sagittal dorsiflexion/plantarflexion (dorsiflexion when the foot touches the ground, plantarflexion during advancement).
Pelvic movements
Time frame: From enrollment to the end of treatment at 2 weeks.
Forward/backward tilt, internal and external rotation, lateral tilt.
Ground Reaction Force (GRF)
Time frame: From enrollment to the end of treatment at 2 weeks.
Measured by a force measuring platform, a typical bimodal curve (first peak ≈ 110% of body weight, second peak ≈ 120% of body weight).
Joint Moments
Time frame: From enrollment to the end of treatment at 2 weeks.
Reflecting the control of muscles and ligaments over joints (such as predicting the risk of osteoarthritis with knee adduction torque).The unit of it is N · m (Newton meters)
Power
Time frame: From enrollment to the end of treatment at 2 weeks.
Joint work efficiency (peak power during ankle joint propulsion is key).The unit it is W.
Symmetry Index
Time frame: From enrollment to the end of treatment at 2 weeks.
The difference in step size and support phase time between the left and right sides (often asymmetric in stroke patients).
Phase Coordination
Time frame: From enrollment to the end of treatment at 2 weeks.
The temporal relationship between the swing phase and the support phase (which may be disrupted in Parkinson's disease patients).
Center of gravity position
Time frame: From enrollment to the end of treatment at 2 weeks.
It refers to the projection position of the center of gravity on the horizontal plane when the human body is standing quietly. By using pressure tablets and other devices, the front, back, left, and right positions of the center of gravity can be measured, reflecting the body's balance state under static conditions. Under normal circumstances, the center of gravity is relatively stable and within the range of the area supported by both feet.
Center of gravity swing amplitude
Time frame: From enrollment to the end of treatment at 2 weeks.
It refers to the maximum distance that the center of gravity deviates from the center position within a certain period of time. The smaller the swing amplitude, the better the static balance ability. Generally measured in millimeters (mm), when healthy adults stand quietly, the amplitude of their center of gravity swing back and forth is usually around 10-20mm, and the amplitude of left and right swing is relatively small.
Center of gravity swing frequency
Time frame: From enrollment to the end of treatment at 2 weeks.
It refers to the number of times the center of gravity swings per unit time. The lower the frequency, the stronger the static balance control capability. When a normal adult stands quietly, the frequency of center of gravity swing is generally between 0.5-2 times per second.
Walking stability
Time frame: From enrollment to the end of treatment at 2 weeks.
It is evaluated by analyzing the step characteristics during walking, including step length, stride length, step frequency, bipedal support time, single foot support time, and other parameters. For example, if the stride is uniform, the stride is stable, the stride frequency is moderate, and the ratio of foot support time to single foot support time is reasonable, it indicates good dynamic balance ability during walking. When adults walk normally, the stride length is about 50-80cm, and the step frequency is around 90-120 steps per minute.
Posture transition ability
Time frame: From enrollment to the end of treatment at 2 weeks.
It measures the stability and coordination during the transition from one posture to another (such as sitting to standing, standing to walking, etc.). The evaluation indicators include conversion time, accuracy of center of gravity shift, and whether additional support or auxiliary movements are needed. Healthy individuals complete posture transitions quickly and smoothly, with a smooth shift of center of gravity, typically without the need for external force or excessive adjustment movements.
Disturbance response ability
Time frame: From enrollment to the end of treatment at 2 weeks.
The ability of the human body to restore balance through its own balance adjustment mechanism when subjected to external disturbances such as sudden thrust, tension, or ground shaking. The relevant parameters include reaction time, maximum offset distance, and time to restore balance. Rapid response, ability to control the body's center of gravity within a small deviation range and quickly restore balance, indicate good disturbance response ability.
Visual dependence level
Time frame: From enrollment to the end of treatment at 2 weeks.
It is evaluated by comparing the balance test results between open and closed eye states. If the balance function significantly decreases after closing the eyes, it indicates a high degree of dependence on visual information; On the contrary, if there is not much difference in balance performance between opening and closing the eyes, it indicates that other balance regulation mechanisms such as proprioception have played a good role. For example, in the test of standing on one foot with closed eyes, the ability to stand for a longer period of time when the eyes are open is significantly reduced, indicating that vision plays an important role in maintaining balance in this posture.
Muscle activity pattern
Time frame: From enrollment to the end of treatment at 2 weeks.
Using techniques such as surface electromyography to record the activation sequence, intensity, and duration of different muscles during balance tasks. Normal balance control requires multiple groups of muscles to work together, and whether the muscle activity pattern is normal or not can reflect the nervous system's ability to control muscles and the coordination and cooperation between muscles. For example, when maintaining balance in a standing position, the calf muscles, hip muscles, and back muscles will contract and relax in a timely manner according to changes in the body's center of gravity to maintain stability.
4 secondary outcomes
anxiety
Time frame: From enrollment to the end of treatment at 2 weeks
sleep quality
Time frame: From enrollment to the end of treatment at 2 weeks
Self efficacy
Time frame: From enrollment to the end of treatment at 2 weeks
Neurotransmitters and Cytokines
Time frame: From enrollment to the end of treatment at 2 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 May 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Stroke
Recruiting
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Stroke, Acute
RecruitingPhase 4
Xeomin® and Gait Related Mobility After Stroke
Stroke
RecruitingObservational study
Implementing Transcranial Direct Current Stimulation in a Rehabilitation Setting
Aphasia, Stroke
Not yet recruiting
EEG Feedback-Based Vagus Nerve Stimulation for Post-Stroke Dysphagia
Ischemic Stroke, Post-stroke Dysphagia
RecruitingObservational study
Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
Moyamoya Disease, Moyamoya Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dynamic hot spring hydrotherapy intervention and Conventional rehabilitation intervention in people with Stroke, run by The Second Affiliated Hospital of Kunming Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Liqing Yao (+8613529202383, yaoliqing98731@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Timed Up and Go Test, (TUG) (time frame: From enrollment to the end of treatment at 2 weeks.). The study lists 51 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2025.